Overview of IBA's Third Quarter 2025 Financial Update
Louvain-la-Neuve, Belgium - IBA (Ion Beam Applications SA), renowned for particle accelerator technology, has presented a comprehensive business update for the third quarter of 2025. This quarter showcases significant advancements and a solid financial structure that reinforces the company’s confidence in meeting its FY2025 guidance.
Business Highlights at a Glance
As of Q3 2025, IBA achieved remarkable milestones, including:
- Equipment order intake reached €195 million, representing a 6% increase from the previous year. The surge is attributed to IBA Technologies, particularly in RadioPharma Solutions, complemented by four sales of the Proteus®ONE systems.
- Stable backlog of €1.3 billion for equipment and services, demonstrating sustained conversion capacity within the company.
- Confirmation of FY2025 REBIT guidance at a minimum of €25 million, buoyed by effective operational management and an encouraging contribution from Proton Therapy.
- Net debt position of €60 million, with ongoing large-scale proton therapy projects contributing to the working capital cycle. The financial position is anticipated to improve gradually starting December.
- Successful launch of a €125 million refinancing deal with leading banks that includes various credit lines structured to enhance operational flexibility.
- Progress in production capabilities through PanTera's new commercial-scale Ac-225 production facility, now operational for clinical trials.
Leadership Insights from Olivier Legrain
Olivier Legrain, the Chief Executive Officer of IBA, expressed optimism regarding the company’s trajectory: “Our strong execution in backlog conversion provides clear visibility towards achieving our FY2025 guidance. The dynamics in our markets remain encouraging due to clinical trial results in proton therapy and heightened engagement in theranostics. The recent refinancing enhances our capacity to meet operational commitments and pursue growth opportunities.”
Proton Therapy Developments
- Current Projects and Installations: IBA is managing 41 projects within its equipment backlog, consisting of various Proteus systems, with 9 installations actively taking place in 2025. This installed base underpins ongoing service sales across 45 active sites globally.
- Commercial Success: The company experienced substantial traction during the quarter, selling four Proteus®ONE systems, with a robust pipeline in North America and continued engagement in the Asia-Pacific region.
- Clinical Advancements: New evidence solidifies proton therapy's effectiveness, especially concerning head and neck cancer treatment compared to conventional radiation, highlighting reduced side effects and improved survival rates.
Strategic Innovations in IBA Technologies
- Updates on Product Portfolio: IBA Technologies continues to demonstrate strength, recording four additional system sales this quarter and reaching a total of 18 systems sold.
- Pioneering Research and Development: Collaborations within the industrial sector are emphasizing shifts towards E-Beam and X-Ray sterilization due to regulatory pressures, while engagement with nuclear medicine continues to expand.
Corporate Refinancing and Growth Strategies
During this quarter, IBA secured a €125 million refinancing package with multiple banks, which is expected to significantly strengthen the company’s financial framework. This package is not only designed to optimize the balance sheet but also provides funds specifically designated for potential mergers and acquisitions.
Preparations for Future Investments
- PanTera's Milestone: The groundbreaking event for its Ac-225 production facility, partnering with Terra Power Isotopes for extensive clinical trial support, marks a significant step forward.
- mi2-factory Development: Finalized specifications push mi2 towards advancements in semiconductor applications, while efforts to obtain necessary funding continue.
- Normandy Hadrontherapy Updates: NHa continues technical advancements, targeting critical project milestones for the coming year.
- New Asia Headquarters: Officially opened in Beijing, this office aims to enhance collaborations with local institutions and improve customer support in the region.
Looking Ahead: FY2025 Guidance
ABA is on a solid path towards achieving at least €25 million in Group REBIT for FY2025, underpinned by robust revenues and a favorable REBIT trajectory from Proton Therapy. Furthermore, the mid-term outlook anticipates a revenue growth of 5-7% CAGR, reflecting sustained market progression.
In light of shifting geopolitical landscapes, IBA remains vigilant and adaptable, particularly regarding challenges and opportunities in the global medical device market.
Frequently Asked Questions
What were IBA's key financial highlights for Q3 2025?
IBA achieved a €195 million order intake, a stable backlog of €1.3 billion, and confirmed a €25 million REBIT guidance for FY2025.
What is the significance of the refinancing deal IBA secured?
The €125 million refinancing deal enhances IBA's financial structure and provides liquidity for operational and strategic initiatives, including potential M&A.
How is IBA expanding its presence in the proton therapy market?
IBA's active projects and sales of the Proteus®ONE systems showcase its commitment to enhancing clinical offerings, backed by solid clinical evidence.
What investments are planned for the future?
IBA is focusing on expanding its production capabilities, particularly its Ac-225 facility, while developing innovative solutions in various technology sectors.
How does IBA plan to address potential risks in the market?
The company actively monitors the geopolitical landscape and is prepared to adapt its strategies to accommodate changes affecting the industry.
